A role for adenosine in sickle-cell anemia
Nature Medicine
December 20, 2010
Excessive adenosine signalling has a pathological role in sickle-cell anaemia, pointing to new therapeutic possibilities against this disease, reports a new study published online this week in Nature Medicine.
In sickle-cell anaemia, red blood cells — erythrocytes — acquire an abnormal shape. Lack of oxygen can be the initial trigger to induce this “sickling”, which eventually leads to organ damage in patients.
Yang Xia and her team found that the concentration of adenosine in the blood was elevated in mice and humans with sickle-cell disease, promoting erythrocyte sickling and rupture. These effects depended on the activation of a specific adenosine receptor, which results in the production of 2,3-diphosphoglycerate, an erythrocyte-specific metabolite that decreases the oxygen binding affinity of hemoglobin. Drugs that target this adenosine receptor may have beneficial effects in people with sickle-cell anaemia.
doi: 10.1038/nm.2280
Research highlights
-
Jul 1
Criminology: Predicting police enforcement bias in major US citiesNature Human Behaviour
-
Jul 1
Evolution: Pandas gave bamboo the thumbs up at least six million years agoScientific Reports
-
Jul 1
Space health: The path of most resistance could help limit bone loss during spaceflightScientific Reports
-
Jun 30
Genomics: Gray wolf genome hints at dual ancestry of dogsNature
-
Jun 30
Evolution: Hawks learn on the fly to swoop up before perchingNature
-
Jun 30
Microbiology: Transmission of gastrointestinal viruses in salivaNature